Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2025

Pharma News, 2025

Simvastatin Does Not Enhance Escitalopram
Simvastatin Does Not Enhance Escitalopram
Data Show Simvastatin Does Not Enhance Escitalopram Response in Comorbid Depression and Obesity
MAIA Biotechnology
MAIA Biotechnology
MAIA Biotechnology publishes preclinical data on cancer drug candidates
Zanubrutinib Outperforms Acalabrutinib in Adjusted Head-to-Head Analysis
Zanubrutinib Outperforms Acalabrutinib in Adjusted Head-to-Head Analysis
An adjusted analysis of the ALPINE and ASCEND trials revealed a statistically significant progression-free survival advantage for Zanubrutinib.
FDA Announces Plan to Phase Out Animal Testing. Will That Work?
FDA Announces Plan to Phase Out Animal Testing. Will That Work?
Human organs-on-chips and organoids offer new alternatives to animals for drug development, but there is still a long way to go.
Sino Biopharma spends $951m to acquire China-based LaNova Medicines
Sino Biopharma spends $951m to acquire China-based LaNova Medicines
Sino Biopharma spends $951m to acquire China-based LaNova Medicines
FDA to review MSD’s doravirine/islatravir NDA for HIV-1
FDA to review MSD’s doravirine/islatravir NDA for HIV-1
FDA to review MSD’s doravirine/islatravir NDA for HIV-1
FDA Receives Resubmitted BLA
FDA Receives Resubmitted BLA
FDA Receives Resubmitted BLA for Tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease
Aviva Biopharm Inc.
Aviva Biopharm Inc.
Aviva Biopharm Inc. Unveils Groundbreaking Pre-Clinical Data on d3-T, a First-in-Class Testosterone Therapy for Women at ENDO 2025
FDA Grants Orphan Drug Designation to Quemliclustat in Pancreatic Cancer
FDA Grants Orphan Drug Designation to Quemliclustat in Pancreatic Cancer
Quemliclustat plus gemcitabine and nab-paclitaxel chemotherapy outperformed median OS benchmarks in patients with metastatic PDAC.
FDA-approved drug can reduce post-surgery pain without heavy opioid use
FDA-approved drug can reduce post-surgery pain without heavy opioid use
Researchers at the Medical University of South Carolina have made a breakthrough in pain management.
CTO East Coast 2025
CTO East Coast 2025
CTO East Coast 2025: Global oncology cell therapy market to hit $25bn by 2031
FDA accepts new supplemental biologics license application for review for Winrevair
FDA accepts new supplemental biologics license application for review for Winrevair
The FDA has accepted for priority review a new supplemental biologics license application for Winrevair to treat adults with advanced pulmonary arterial hypertension, according to a press release from...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand